Skip to main content
. 2018 Aug 13;9:889. doi: 10.3389/fphar.2018.00889

FIGURE 6.

FIGURE 6

CD63 exosomal marker is reduced following 1 h CBD treatment in HEPG2, PC3, and MDA-MB-231 cancer cells. The results from the NTA analysis were confirmed by Western blotting for the exosomal CD63 marker, which was reduced in all three cell lines following 1 h treatment with 5 μM CBD: (A) CD63 expression is reduced in CBD treated versus DMSO control treated HEPG2 cancer cells; (B) CD63 expression is reduced in CBD treated versus DMSO control treated PC3 cells; (C) CD63 expression is reduced in CBD treated versus DMSO control treated MDA-MB-231 cells. All EMV preparations were performed in equal buffer volume (50 μl) and all cell lysates were prepared in equal buffer volume (50 μl) between all samples, for accurate presentation of amounts of vesicles isolated and amounts of cells grown and collected per flask. For EMV isolates, 20 μl of sample was loaded per lane, while for β-actin detection in the corresponding cell lysates, 10 μl of sample was loaded per lane. The relative detection of CD63 in EMVs released from the corresponding cell preparation is indicated by “R,” in relation to β-actin detection in the corresponding cell isolate, for comparison between CBD treatments versus DMSO control.